Abstract
The APJ is a class A, rhodopsin-like G protein-coupled receptor (GPCR) with high sequence similarity to the angiotensin receptor AT1. APJ has been shown to be widely expressed in humans tissues, including the central nervous system, cardiovascular system, adipocytes and others. APJ plays an important role in the occurrence and development of cardiovascular and metabolic diseases including atherosclerosis (AS), coronary heart disease (CAD), heart failure(HF), pulmonary arterial hypertension (PAH), myocardial hypertrophy and atrial fibrillation, especially hypertension. Previous researchers found that apelin/APJ could induce vasodilation and then reduce blood pressure. Despite APJ is closely associated with many diseases, there are no drugs that can activate or inhibit APJ directly. In the current review, we have summarized recently reported peptides, small molecule agonists and antagonists targeting APJ. Given the role of apelin/APJ in hypertension and other cardiovascular diseases, we believe that the peptides and compounds based on APJ will be developed for treatment of these diseases.
Keywords: Agonists, antagonists, anti-hypertension, apelin, APJ, novel compounds, target.
Current Drug Targets
Title:Targeting Drugs to APJ Receptor: The Prospect of Treatment of Hypertension and Other Cardiovascular Diseases
Volume: 16 Issue: 2
Author(s): Jiangang Cao, Hening Li and Linxi Chen
Affiliation:
Keywords: Agonists, antagonists, anti-hypertension, apelin, APJ, novel compounds, target.
Abstract: The APJ is a class A, rhodopsin-like G protein-coupled receptor (GPCR) with high sequence similarity to the angiotensin receptor AT1. APJ has been shown to be widely expressed in humans tissues, including the central nervous system, cardiovascular system, adipocytes and others. APJ plays an important role in the occurrence and development of cardiovascular and metabolic diseases including atherosclerosis (AS), coronary heart disease (CAD), heart failure(HF), pulmonary arterial hypertension (PAH), myocardial hypertrophy and atrial fibrillation, especially hypertension. Previous researchers found that apelin/APJ could induce vasodilation and then reduce blood pressure. Despite APJ is closely associated with many diseases, there are no drugs that can activate or inhibit APJ directly. In the current review, we have summarized recently reported peptides, small molecule agonists and antagonists targeting APJ. Given the role of apelin/APJ in hypertension and other cardiovascular diseases, we believe that the peptides and compounds based on APJ will be developed for treatment of these diseases.
Export Options
About this article
Cite this article as:
Cao Jiangang, Li Hening and Chen Linxi, Targeting Drugs to APJ Receptor: The Prospect of Treatment of Hypertension and Other Cardiovascular Diseases, Current Drug Targets 2015; 16 (2) . https://dx.doi.org/10.2174/1389450115666141128120053
DOI https://dx.doi.org/10.2174/1389450115666141128120053 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Modulation of Gi Proteins in Hypertension: Role of Angiotensin II and Oxidative Stress
Current Cardiology Reviews Protecting the Heart: Biological Targets and Clinical Strategies
Current Pharmaceutical Design Renal Endothelial Dysfunction in Diabetic Nephropathy
Cardiovascular & Hematological Disorders-Drug Targets Intrauterine Intervention for the Treatment of Fetal Growth Restriction
Current Pediatric Reviews Optimal Medical Therapy for Coronary Artery Disease in 2011 – Perspectives from the STICH Trial
Cardiovascular & Hematological Agents in Medicinal Chemistry Cancer Risk and Nullity of Glutathione-S-Transferase Mu and Theta 1 in Occupational Pesticide Workers
Current Pharmaceutical Biotechnology QT Prolongation and Anticancer Drugs: Is it a Cardiologist’s Worry? The Oncologist’s Point of View
Reviews on Recent Clinical Trials Obesity and Body Composition in Man and Woman: Associated Diseases and the New Role of Gut Microbiota
Current Medicinal Chemistry Novel, Unifying Phagomimetic Mechanism of Vancomycin Therapeutic Action and Toxicity: Polyphenol, Electron Transfer and Reactive Oxygen Species
Anti-Infective Agents in Medicinal Chemistry The Aromatic Stacking Interactions Between Proteins and their Macromolecular Ligands
Current Protein & Peptide Science Insights into the Pathogenesis and Intervention of Atherosclerosis
Vascular Disease Prevention (Discontinued) Breastfeeding and Diabetes
Current Diabetes Reviews Insulin Resistance and Polycystic Ovary Syndrome Through Life
Current Pharmaceutical Design Clinically Relevant Extracellular-Matrix Scaffolds for Cell Transplantation and Vascular Repair
Current Vascular Pharmacology Diabetic Vascular Complications: Pathophysiology, Biochemical Basis and Potential Therapeutic Strategy
Current Pharmaceutical Design Drugs Targeting the Canonical NF-κB Pathway to Treat Viral and Autoimmune Myocarditis
Current Pharmaceutical Design The Role of Streptokinase as a Virulence Determinant of Streptococcus pyogenes – Potential for Therapeutic Targeting
Current Drug Targets Functional and Structural Benefits Induced by Omega-3 Polyunsaturated Fatty Acids During Aging
Current Neuropharmacology Antibacterial and Antioxidant Property of Streptomyces cinnamonensis VITNS1 Isolated from Serkadu Region, Vellore, Tamil Nadu, India
Anti-Infective Agents Relaxin Receptors - New Drug Targets for Multiple Disease States
Current Drug Targets